On October 4, 1990, the Food and Drug Administration (FDA) approved labeling stating that one of the currently licensed Haemophilus influenzae type b conjugate vaccines, commonly designated as HbOC, is safe and effective for administration to infants beginning at 2 months of age. The Committee has reviewed the available information regarding the safety, immunogenicity, and efficacy of HbOC and other licensed conjugate vaccines (see Table 1) and has formulated new recommendations and guidelines for H influenzae type b immunization.

This content is only available via PDF.